Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Aug;64(2):274–280. doi: 10.1038/bjc.1991.291

Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.

D J Flavell 1, S Cooper 1, B Morland 1, S U Flavell 1
PMCID: PMC1977495  PMID: 1716453

Abstract

We have investigated the efficacy of a F(ab'gamma)2 bispecific antibody (BsAb) with dual specificity for the CD7 molecule in one Fab arm and for the ribosome inactivating protein (rip) saporin in the other arm, for delivering saporin to the acute T-cell leukaemia cell line HSB-2. Saporin titration experiments revealed that BsAb increased the toxicity of saporin 435-fold for HSB-2 cells, reducing the IC50 for saporin alone from 0.1 mumol to 0.23 nmol when BsAb was included. The rate of protein synthesis inactivation brought about by BsAb-mediated toxin delivery to HSB-2 cells was very similar to that described for conventional immunotoxins (IT's) with a t10 (time taken for a one log inhibition of protein synthesis compared with controls) of 46 h obtained at a saporin concentration of 1 nmol and 226 h at 0.1 nmol. BsAb titration studies demonstrated a clear dose response effect of BsAb concentration on target cell protein synthesis inhibition and cell proliferation. The absolute specificity of toxin delivery was unequivocally demonstrated by a failure of BsAb to deliver an effective dose of saporin to the CD7- cell line HL60 and by the blocking of BsAb-mediated delivery of saporin to HSB-2 cells with an excess of F(ab)2 fragments of the anti-CD7 antibody, HB2. These studies have clearly demonstrated the effectiveness of this BsAb for delivering saporin to a T-ALL cell line utilising CD7 as the target molecule on the cell surface. BsAb's would therefore appear to offer a realistic alternative to IT's for toxin delivery to tumour cells and may even offer certain advantages over conventional IT's for clinical use.

Full text

PDF
274

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blakey D. C., Skilleter D. N., Price R. J., Watson G. J., Hart L. I., Newell D. R., Thorpe P. E. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells. Cancer Res. 1988 Dec 15;48(24 Pt 1):7072–7078. [PubMed] [Google Scholar]
  2. Bregni M., Siena S., Formosa A., Lappi D. A., Martineau D., Malavasi F., Dorken B., Bonadonna G., Gianni A. M. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells. Blood. 1989 Feb 15;73(3):753–762. [PubMed] [Google Scholar]
  3. Butturini A., Bortin M. M., Gale R. P. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant. 1987 Oct;2(3):233–242. [PubMed] [Google Scholar]
  4. Casellas P., Bourrie B. J., Gros P., Jansen F. K. Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem. 1984 Aug 10;259(15):9359–9364. [PubMed] [Google Scholar]
  5. Champlin R., Gale R. P. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood. 1989 Jun;73(8):2051–2066. [PubMed] [Google Scholar]
  6. FitzGerald D. J., Willingham M. C., Pastan I. Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6627–6630. doi: 10.1073/pnas.83.17.6627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ghetie M. A., May R. D., Till M., Uhr J. W., Ghetie V., Knowles P. P., Relf M., Brown A., Wallace P. M., Janossy G. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 1988 May 1;48(9):2610–2617. [PubMed] [Google Scholar]
  8. Glennie M. J., Brennand D. M., Bryden F., McBride H. M., Stirpe F., Worth A. T., Stevenson G. T. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma. J Immunol. 1988 Nov 15;141(10):3662–3670. [PubMed] [Google Scholar]
  9. Glennie M. J., McBride H. M., Worth A. T., Stevenson G. T. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol. 1987 Oct 1;139(7):2367–2375. [PubMed] [Google Scholar]
  10. Goldmacher V. S., Anderson J., Schulz M. L., Blättler W. A., Lambert J. M. Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins. J Biol Chem. 1987 Mar 5;262(7):3205–3209. [PubMed] [Google Scholar]
  11. Hertler A. A., Frankel A. E. Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol. 1989 Dec;7(12):1932–1942. doi: 10.1200/JCO.1989.7.12.1932. [DOI] [PubMed] [Google Scholar]
  12. Kamel-Reid S., Letarte M., Sirard C., Doedens M., Grunberger T., Fulop G., Freedman M. H., Phillips R. A., Dick J. E. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science. 1989 Dec 22;246(4937):1597–1600. doi: 10.1126/science.2595371. [DOI] [PubMed] [Google Scholar]
  13. Kersey J. H., Weisdorf D., Nesbit M. E., LeBien T. W., Woods W. G., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med. 1987 Aug 20;317(8):461–467. doi: 10.1056/NEJM198708203170801. [DOI] [PubMed] [Google Scholar]
  14. Laurent G., Frankel A. E., Hertler A. A., Schlossman D. M., Casellas P., Jansen F. K. Treatment of leukemia patients with T101 ricin A chain immunotoxins. Cancer Treat Res. 1988;37:483–491. doi: 10.1007/978-1-4613-1083-9_27. [DOI] [PubMed] [Google Scholar]
  15. Laurent G., Kuhlein E., Casellas P., Canat X., Carayon P., Poncelet P., Correll S., Rigal F., Jansen F. K. Determination of sensitivity of fresh leukemia cells to immunotoxins. Cancer Res. 1986 May;46(5):2289–2294. [PubMed] [Google Scholar]
  16. Myers C. D., Thorpe P. E., Ross W. C., Cumber A. J., Katz F. E., Tax W., Greaves M. F. An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A. Blood. 1984 May;63(5):1178–1185. [PubMed] [Google Scholar]
  17. Press O. W., Hansen J. A., Farr A., Martin P. J. Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res. 1988 Apr 15;48(8):2249–2257. [PubMed] [Google Scholar]
  18. Ramakrishnan S., Houston L. L. Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine. Science. 1984 Jan 6;223(4631):58–61. doi: 10.1126/science.6318313. [DOI] [PubMed] [Google Scholar]
  19. Raso V., Basala M. A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells. J Biol Chem. 1984 Jan 25;259(2):1143–1149. [PubMed] [Google Scholar]
  20. Scott C. F., Jr, Lambert J. M., Goldmacher V. S., Blatter W. A., Sobel R., Schlossman S. F., Benacerraf B. The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies. Int J Immunopharmacol. 1987;9(2):211–225. doi: 10.1016/0192-0561(87)90096-8. [DOI] [PubMed] [Google Scholar]
  21. Stirpe F., Gasperi-Campani A., Barbieri L., Falasca A., Abbondanza A., Stevens W. A. Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree). Biochem J. 1983 Dec 15;216(3):617–625. doi: 10.1042/bj2160617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stong R. C., Uckun F., Youle R. J., Kersey J. H., Vallera D. A. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood. 1985 Sep;66(3):627–635. [PubMed] [Google Scholar]
  23. Thorpe P. E., Brown A. N., Bremner J. A., Jr, Foxwell B. M., Stirpe F. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst. 1985 Jul;75(1):151–159. [PubMed] [Google Scholar]
  24. Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Blakey D. C., Newell D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 1988 Nov 15;48(22):6396–6403. [PubMed] [Google Scholar]
  25. Webb K. S., Ware J. L., Parks S. F., Walther P. J., Paulson D. F. Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy. Cancer Treat Rep. 1985 Jun;69(6):663–672. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES